Skip to content

Journey Medical Corporation DERM Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

PTH
Pelthos Therapeutics Inc.PTHS
-$1.91M
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$20.77M+9,805%
HRO
HarrowHROW
-$1.2M+36.5%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
-$9.21M-261%
Pulse Biosciences, Inc. logo
Pulse Biosciences, Inc.PLSE
$1.83M+160%
VAT
InnovateVATE

Other financials

Income statement

See full
Revenue$16.0M+21.5%
Gross profit$9.7M+16.7%
Operating income-$1.5M+55.1%
Net income-$2.2M+45.2%
EPS (diluted)-$0.08+55.6%

Balance sheet

See full
Cash & equivalents$27.2M+29.2%
Total debt$25.5M+1.2%
Total equity$30.8M+43.1%
Total assets$91.5M+7.7%

Cash flow

See full
Operating cash flow$2.9M+203%
CapEx$3.8M
Free cash flow-$6.0M

Valuation

See full
Market cap$194.94M+20.9%
Enterprise value$193.19M+16.2%
P/S+0.2×

Profitability

See full
Gross margin65.4%-1.0pp
Operating margin-9.8%
Net margin-14.8%
FCF margin-43%

Returns & leverage

See full
Return on equity-36.6%
Debt / equity0.8×-0.3×
Current ratio1.7×+0.4×

Where this comes from

Reported directly by Journey Medical Corporation in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: Journey Medical Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Journey Medical Corporation's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Journey Medical Corporation's change in accrued liabilities?
Journey Medical Corporation (DERM) reported change in accrued liabilities of -$1.47M in Q1 2026.
How has Journey Medical Corporation's change in accrued liabilities changed year-over-year?
Journey Medical Corporation's change in accrued liabilities decreased by 126.2% year-over-year, from $5.59M to -$1.47M.
What does change in accrued liabilities mean?
Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.